Published in Cancer Weekly, June 2nd, 2009
All of the clinical data to be presented demonstrates the potential clinical efficacy of KRX-0401, both as a single agent and in combination with other approved agents, in the treatment of patients with advanced renal cell carcinoma, colorectal cancer and GIST.
Keywords: Biopharmaceuticals, Biotechnology Business,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.